Debt and Dividends: AbbVie's High Stakes Gamble on Apogee AbbVie's $10.
6 billion planned acquisition of Apogee Therapeutics has raised eyebrows among dividend investors, who have come to rely on the pharmaceutical giant's consistent payouts.
The deal has sparked debate about the company's significant debt load and its implications for the broader pharmaceutical landscape.